Skip to main content

Relias Media has upgraded our site!

Please bear with us as we work through some issues in order to provide you with a better experience.

Thank you for your patience.

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

<p>In this section: The FDA approves new chronic hepatitis C treatment, greenlights a treatment course for primary biliary cirrhosis, and strengthens warning about the risk of acute kidney injury in several diabetes medications.</p>

FDA Actions